Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy

详细信息    查看全文

• 作者：George Papatheodoridis ; John Goulis ; Spilios Manolakopoulos ; Aikaterini Margariti ; Xenofon Exarchos ; Georgios Kokkonis ; Emilia Hadziyiannis ; Christos Papaioannou ; Emanuel Manesis ; Dimitrios Pectasides ; Evangelos Akriviadis
• 关键词：HBeAg ; hepatitis B e antigen ; NA(s) ; nucleos(t)ide analogue(s) ; HBV ; hepatitis B virus ; HBsAg ; hepatitis B surface antigen ; anti-HBe ; antibody against HBeAg ; ALT ; alanine aminotransferase ; ULN ; upper limit of normal ; PCR ; polymerase chain reaction ; LSM ; liver stiffness measurement ; IQR ; interquartile range ; SD ; standard deviation
• 刊名：Journal of Hepatology
• 出版年：January, 2014
• 年：2014
• 卷：60
• 期：1
• 页码：62-68
• 全文大小：765 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Background & Aims

Serum HBsAg levels might represent an important predictor of sustained off-treatment response in HBeAg-negative chronic hepatitis B (CHB). We evaluated the changes of HBsAg and interferon-inducible protein 10 (IP10) serum levels in HBeAg-negative CHB patients treated with entecavir.

Methods

114 patients received entecavir for a median of 4.3 years. HBsAg levels were determined at baseline, 6 and 12 months and every year thereafter until year-4. IP10 levels were measured at baseline and annually until year-4 in 76 patients.

Results

Virological remission rates were high (year-1: 94%, after year-2: 97-98%). Compared to baseline, HBsAg levels decreased by a median of 0.03, 0.13, 0.17, 0.22, and 0.32 log₁₀ IU/ml at 6 months and 1, 2, 3, and 4 years, respectively (p 猢?.001 for all comparisons). The proportions of patients with HBsAg decline of 猢?.5 or 猢? log₁₀ IU/ml were 9% or 6% at year-1 and 21% or 10% at the last visit. Median IP10 levels (pg/ml) did not change from baseline to year-1 or -2 (245 vs. 229 or 251), but increased at year-3 and -4 (275 and 323, p <0.030). HBsAg drop 猢?.5 log₁₀ was associated with baseline IP10 or IP10 >350 pg/ml (p 猢?.002). HBsAg loss occurred in 4/114 (3.5%) patients or in 1/2, 3/21, and 0/91 patients with baseline HBsAg <100, 100-1000 and >1000 IU/ml, respectively (p <0.001).

Conclusions

In HBeAg-negative CHB patients, 4-year entecavir therapy decreases serum HBsAg levels, but the rate of decline is rather slow. Serum IP10 levels represent a promising predictor of HBsAg decline in this setting.